Management of infected stone disease with hydroxyurea: a five year follow-up.
Hydroxyurea in a morning dose of 500 mg along with Macrodantin, 100 mg, has been used for more than five years as an adjunct to the management of retained struvite stones. Mild reversible toxicity occurs in 10 per cent. Urine sterility can be achieved in ninety per cent and no growth of the retained stone occurs.
D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007669:Kidney Calculi / Q000150:complications / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy*
D006918:Hydroxyurea